Metastatic Renal Cell Carcinoma Change Vascularity

الملخص EN

Several molecular targeted agents have been approved for clinical use for metastatic renal cell carcinoma (mRCC).

A case of a 32-year-old woman with mRCC is presented.

These tumors could change vascularity by administration of molecular agents.

We could select a drug timely based on findings of computed tomography.

To our knowledge, this is the first report that tumor’s character change induced by molecular targeted agents can be detected and the efficacy of molecular targeted agents can be predicted.